Last reviewed · How we verify
Continuous infusion of Phenylephrine
Continuous infusion of Phenylephrine, marketed by Hassan II University, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Continuous infusion of Phenylephrine |
|---|---|
| Sponsor | Hassan II University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock (PHASE3)
- Norepinephrine vs. Phenylephrine for Hypotension in Low-Dose Spinal Anesthesia for Cesarean Delivery (PHASE4)
- Norepinephrine vs Phenylephrine During General Anesthesia (PHASE4)
- Ephedrine Versus Phenylephrine for Spinal Block - Related Hypotension in Cesarean Delivery
- Continuous Infusion of Norepinephrine vs Phenylephrine During Spinal Anesthesia for Cesarean Section (INPEACE) (PHASE4)
- Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes (PHASE4)
- Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity (EARLY_PHASE1)
- Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous infusion of Phenylephrine CI brief — competitive landscape report
- Continuous infusion of Phenylephrine updates RSS · CI watch RSS
- Hassan II University portfolio CI